文献速递免疫规划慢病防控与筛查传染病防控与疫情报告

炎症性风湿病患者肺炎球菌与流感疫苗接种覆盖率及其对COVID-19感染严重程度的影响:法国国家医疗数据库分析

Pneumococcal and influenza vaccination coverage and impact on COVID-19 infection severity in patients with inflammatory rheumatic diseases: A French National Healthcare Database analysis.
PubMed 文献 · Vaccine · 2025-07-01

该研究基于法国国家医疗数据库(SNDS)纳入406156例炎症性风湿病患者,评估肺炎球菌和流感疫苗接种对COVID-19严重程度的影响及接种覆盖率。肺炎球菌疫苗接种与住院、重症和死亡风险降低相关,而流感疫苗接种与这些结局风险升高相关;肺炎球菌和流感疫苗接种率分别为37.8%和40.5%。

要点

  • 肺炎球菌疫苗接种与COVID-19住院风险(OR 0.84)、重症(OR 0.83)和死亡(OR 0.82)降低相关。
  • 流感疫苗接种与COVID-19住院(OR 1.47)、重症(OR 1.54)和死亡(OR 1.62)风险升高相关。
  • 该人群中肺炎球菌和流感疫苗接种率分别为37.8%和40.5%。

核心结论

  • 肺炎球菌疫苗接种与感染患者住院率降低及COVID-19重症(包括死亡)发生减少相关。
  • 这些发现提示疫苗诱导的训练免疫可能参与塑造对其他感染(尤其是COVID-19)的免疫反应。

研究设计与样本

  • 在法国行政与医疗数据库(SNDS)中开展的纵向研究。
  • 识别患有类风湿关节炎(RA)、脊柱关节炎(SpA)和银屑病关节炎(PsA)中一种炎症性风湿病的患者。
  • 使用CIM-10编码识别COVID-19感染患者,并从数据库中提取疫苗接种状态。
  • 共识别406156例患者,其中女性64.6%,平均年龄62.2岁。

主要发现

  • 该人群中肺炎球菌和流感疫苗接种率分别为37.8%和40.5%。
  • 记录到0.9%的COVID-19住院(n=3574)、0.24%的重症感染(n=980)和0.17%的死亡(n=697)。
  • 多因素分析显示肺炎球菌疫苗接种与住院风险降低相关(OR 0.84,95%CI 0.78-0.91,p<0.0001)。
  • 肺炎球菌疫苗接种与重症COVID-19风险降低相关(OR 0.83,95%CI 0.72-0.96,p<0.05),与死亡风险降低相关(OR 0.82,95%CI 0.70-0.97,p<0.05)。
  • 流感疫苗接种与住院风险升高相关(OR 1.47,95%CI 1.36-1.58,p<0.0001),与重症风险升高相关(OR 1.54,95%CI 1.33-1.78,p<0.0001),与死亡风险升高相关(OR 1.62,95%CI 1.36-1.93,p<0.0001)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: It has been suggested that vaccinations could induce a trained immunity able to decrease COVID-19 severity. Our primary aim was to evaluate the COVID-19 severity among patients with inflammatory rheumatic diseases (IRD) vaccinated against pneumococcus and influenza compared to those not vaccinated. A secondary objective was also to determine vaccination coverage within real-life population of IRD patients in France. METHODS: We conducted a longitudinal study within the French administrative and medical data base (SNDS). We have identified patients with one following of these IRD: rheumatoid arthritis (RA), spondyloarthritis (SpA) and psoriatic arthritis (PsA). COVID-19 infected patients were identified using CIM-10 code and vaccination status was extracted from the database. RESULTS: 406,156 patients were identified, with 64.6 % women and a mean age of 62.2 years. Pneumococcal and influenza vaccination rate in this population were respectively 37.8 % and 40.5 %. We recorded 0.9 % COVID-19 hospitalizations (n = 3574), 0.24 % severe infections (n = 980), and 0.17 % deaths (n = 697). Multivariate analysis demonstrated pneumococcal vaccination's association with decreased risks of hospitalization (OR 0.84 IR95 %[0.78-0.91] p < 0.0001), severe COVID-19 forms (OR 0.83 IR95 %[0.72-0.96] p < 0.05), and death (OR 0.82 IR95 %[0.70-0.97] p < 0.05), while influenza vaccination associated with increased risks of these outcomes (OR 1.47 IR95 %[1.36-1.58] p < 0.0001, OR 1.54 IR95 %[1.33-1.78] p < 0.0001, OR 1.62 IR95 %[1.36-1.93] p < 0.0001, respectively). CONCLUSIONS: Pneumococcal vaccination was associated with a reduced hospitalization rate, and occurrence of severe forms of COVID-19, including death, among infected patients. These findings suggest the possible involvement of vaccine-induced trained immunity in shaping the immune response to other infections especially COVID-19.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Auroux M, Fabacher T, Sauleau E, et al. Pneumococcal and influenza vaccination coverage and impact on COVID-19 infection severity in patients with inflammatory rheumatic diseases: A French National Healthcare Database analysis. Vaccine. 2025. PMID: 40602345. doi:10.1016/j.vaccine.2025.127439

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。